H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data

H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with its dual GLP-1/GIP asset VK2735. The data collected in the Phase 1 assessing oral VK2735 is at 28 days exhibited up to an 8.2% reduction in body weight was observed, and oral VK2735 maintained excellent tolerability profile through 100 mg dose level with 99% of adverse events being mild to moderate, the analyst tells investors in a research note. H.C. Wainwright believes Viking’s oral formulation of VK2735 “remains differentiated in the space” in terms of mechanism, efficacy, and safety. It keeps a Buy rating on Viking shares with a $102 price target. The stock in midday trading is down 2% to $23.22.